We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+15.54%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$855M
AUM Growth
+$208M
Cap. Flow
+$133M
Cap. Flow %
15.53%
Top 10 Hldgs %
33.51%
Holding
104
New
21
Increased
54
Reduced
10
Closed
11

Top Buys

Rank Stock Value
1
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
+$28.3M
2
STJ
St Jude Medical
STJ
+$21.6M
3
TRNX
TORNIER N V SHARES (NLD)
TRNX
+$9.49M
4
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$9.39M
5
XLV icon
State Street Health Care Select Sector SPDR ETF
XLV
+$9.37M

Top Sells

Rank Stock Value
1
TMO icon
Thermo Fisher Scientific
TMO
+$13.2M
2
GILD icon
Gilead Sciences
GILD
+$11.2M
3
PCRX icon
Pacira BioSciences
PCRX
+$9.89M
4
ATHN
Athenahealth, Inc.
ATHN
+$8.92M
5
CAH icon
Cardinal Health
CAH
+$6.91M

Sector Composition

Rank Sector Weight
1 Healthcare 73.14%
2 Financials 1.36%
3 Technology 0.94%
4 Industrials 0.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ISRG icon
26
Intuitive Surgical
ISRG
$134B
$9.79M 1.14%
166,500
– –
SRGA
27
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$9.67M 1.13%
62,000
+13
+0% +$1.87K
XLV icon
28
State Street Health Care Select Sector SPDR ETF
XLV
$42.7B
$9.57M 1.12%
+140,000
New +$9.37M
CI icon
29
Cigna
CI
$74.6B
$9.57M 1.12%
93,000
+18,000
+24% +$1.77M
TRNX
30
DELISTED
TORNIER N V SHARES (NLD)
TRNX
$9.5M 1.11%
+372,500
New +$9.49M
BHC icon
31
Bausch Health
BHC
$2.34B
$9.05M 1.06%
63,250
+7,250
+13% +$975K
DHR icon
32
Danaher
DHR
$144B
$9.04M 1.06%
156,966
+30,500
+24% +$1.65M
SLXP
33
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
$8.91M 1.04%
+77,500
New +$9.39M
HTWR
34
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
$8.81M 1.03%
120,000
+38,000
+46% +$2.89M
CBST
35
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
$8.81M 1.03%
87,500
+41,000
+88% +$3.19M
COO icon
36
Cooper Companies
COO
$14.5B
$8.75M 1.02%
216,000
-59,000
-21% -$2.37M
INCY icon
37
Incyte
INCY
$24.4B
$8.26M 0.97%
113,000
+10,000
+10% +$653K
NBIX icon
38
Neurocrine Biosciences
NBIX
$16.6B
$8.04M 0.94%
360,000
+45,000
+14% +$853K
RCPT
39
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$7.96M 0.93%
65,000
+42,500
+189% +$4.3M
JUNO
40
DELISTED
Juno Therapeutics, Inc.
JUNO
$7.54M 0.88%
+144,426
New +$6.46M
VRTX icon
41
Vertex Pharmaceuticals
VRTX
$126B
$7.48M 0.88%
63,000
+5,500
+10% +$619K
COR icon
42
Cencora
COR
$61.2B
$7.21M 0.84%
+80,000
New +$6.86M
PRGO icon
43
Perrigo
PRGO
$1.78B
$7.1M 0.83%
42,500
+14,000
+49% +$2.19M
TSRO
44
DELISTED
TESARO, Inc.
TSRO
$6.97M 0.82%
187,500
+10,000
+6% +$309K
PRAH
45
DELISTED
PRA Health Sciences, Inc.
PRAH
$6.9M 0.81%
+285,000
New +$6.42M
RAD
46
DELISTED
Rite Aid Corporation
RAD
$6.9M 0.81%
45,865
+150
+0.3% +$16.7K
MDCO
47
DELISTED
Medicines Co
MDCO
$6.82M 0.8%
246,300
+98,050
+66% +$2.43M
MWIV
48
DELISTED
MWI VETERINARY SUPPLY, INC.
MWIV
$6.63M 0.78%
39,000
– –
KITE
49
DELISTED
Kite Pharma, Inc.
KITE
$6.6M 0.77%
114,474
+32,000
+39% +$1.35M
SRCL
50
DELISTED
Stericycle Inc
SRCL
$6.55M 0.77%
50,000
+3,000
+6% +$378K
1
2
3 4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q4 2014 Portfolio in Review

As of Q4 2014, Rock Springs Capital Management held 104 positions worth $855M, up 32% from $646M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Rock Springs Capital Management deployed $133M of net new capital in Q4 2014, opening 21 new positions and adding to 54 existing holdings. Its largest new stake was COVIDIEN PLC COM SHS NEW (IRELAND): 295,000 shares worth $30.2M.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, down from 79% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Gilead Sciences, an estimated $11.2M trimmed.

  • Rock Springs Capital Management's largest Q4 2014 buy was COVIDIEN PLC COM SHS NEW (IRELAND): 295,000 shares worth $30.2M.
  • Rock Springs Capital Management added most to Acadia Healthcare in Q4 2014, an estimated $7.38M increase.
  • Rock Springs Capital Management's biggest Q4 2014 reduction was Gilead Sciences, cutting an estimated $11.2M.
  • Rock Springs Capital Management fully exited Thermo Fisher Scientific in Q4 2014, selling an estimated $13.2M.
  • Rock Springs Capital Management's ten largest holdings make up 34% of its $855M portfolio in Q4 2014.
  • Rock Springs Capital Management opened 21 new positions and closed 11 in Q4 2014.
  • Rock Springs Capital Management's portfolio value rose 32% quarter-over-quarter to $855M.

Based on Rock Springs Capital Management's 13F filing for Q4 2014, filed 17 Feb 2015.